TRIANA Biomedicines
Patrick Trojer, PhD, is the Chief Executive Officer and President of TRIANA Biomedicines, a biotechnology company in Greater Boston focused on molecular glue discovery for challenging disease targets, utilizing advanced structural insights and AI-driven drug discovery methods since November 2021. In addition to this role, Patrick serves on the Scientific Advisory Board for Fulcrum Therapeutics and as an advisor for RA Capital Management, L.P. and BiOrigin, all starting in 2022. Previously, Patrick held various leadership positions at Constellation Pharmaceuticals from 2010 to 2021, including Chief Scientific Officer and Vice President of Research. Patrick earned a Ph.D. in Biochemistry and Molecular Biology and an MS in Microbiology and Biochemistry, both from Universität Innsbruck.
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.